Guidelines doi:10.1093/rheumatology/keq249a BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

lines for the use of anti-TNF drugs in RA [1, 2]. These guidelines indicated which adult RA patients should be eligible for treatment, precautions that need to be taken in the use of anti-TNF and action that should be taken in the event of adverse effects. Previous guidelines applied to the then available anti-TNF drugs [etanercept and inflix-imab in 2001, and etanercept, infliximab and adalimumab (first generation anti-TNF agents) in 2005]. Due to the large volume of information now available on these agents, the BSR has produced separate guidelines on eligibility for anti-TNF treatment in RA [3]. These current guidelines cover the safety aspects of anti-TNF in RA and apply to the first generation, but also to the newly licensed second-generation anti-TNF drugs, (certolizumab pegol and goli-mumab). This is a rapidly changing field with new dat